The aim of the present study was to evaluate the prognostic role of the biomarkers CD133, AXL and c-MYC and their association with clinicopathologic characteristics in colorectal adenocarcinomas and adenomas, in a single institutional patient outcome. This evidence concerns the gene AXL and colorectal adenocarcinoma.